Identification of Long Non-Coding RNA MIR4435-2HG as a Prognostic Biomarker in Bladder Cancer.
BCG
biomarkers
bladder cancer
lncRNA
prognosis
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
17 08 2022
17 08 2022
Historique:
received:
15
06
2022
revised:
05
08
2022
accepted:
08
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
The abnormal expression of long non-coding RNAs(lncRNAs) is closely related to the prognosis of patients. This finding may indicate a new target for the treatment of malignant tumors. Non-muscle invasive bladder cancer (NMIBC) is the most common subtype of bladder cancer, and BCG intravesical therapy is the first-line treatment for NMIBC, but about half of NMIBC patients relapse within two years after BCG treatment. Therefore, it is necessary to screen out lncRNAs related to the prognosis and treatment of BGC-resistant patients. Here, we performed differential expression analysis of lncRNAs in the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, and screened
Identifiants
pubmed: 36011373
pii: genes13081462
doi: 10.3390/genes13081462
pmc: PMC9408477
pii:
doi:
Substances chimiques
BCG Vaccine
0
Biomarkers
0
MIR4435-2HG long non-coding RNA, human
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Eur Urol. 2013 Mar;63(3):462-72
pubmed: 23141049
APMIS. 2020 Feb;128(2):92-103
pubmed: 31755155
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Genome Med. 2019 May 24;11(1):34
pubmed: 31126321
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Rev Cancer. 2021 Jan;21(1):22-36
pubmed: 33082563
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Onco Targets Ther. 2018 Oct 04;11:6415-6424
pubmed: 30323619
Clin Cancer Res. 2020 Feb 15;26(4):882-891
pubmed: 31712383
Mol Med Rep. 2018 Nov;18(5):4725-4732
pubmed: 30221669
Mol Med Rep. 2022 Jan;25(1):
pubmed: 34859256
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Int J Mol Med. 2021 Jun;47(6):
pubmed: 33846784
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Nat Commun. 2021 Apr 16;12(1):2301
pubmed: 33863885
J Cell Mol Med. 2019 Feb;23(2):1396-1405
pubmed: 30467945
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Genome Biol. 2014;15(12):550
pubmed: 25516281
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Mol Med Rep. 2019 Aug;20(2):1866-1872
pubmed: 31257499
Aging (Albany NY). 2019 Sep 4;11(17):6657-6673
pubmed: 31484163
Eur Urol. 2011 Sep;60(3):423-30
pubmed: 21621906
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Nat Rev Genet. 2011 Nov 18;12(12):861-74
pubmed: 22094949
Nat Rev Drug Discov. 2017 Mar;16(3):167-179
pubmed: 27444227
Br J Cancer. 2018 Dec;119(12):1477-1486
pubmed: 30374124
Nat Rev Cancer. 2018 Jan;18(1):5-18
pubmed: 29170536
Biomed Pharmacother. 2020 Sep;129:110393
pubmed: 32559616
Mol Cancer. 2018 Sep 29;17(1):142
pubmed: 30268126
Transl Androl Urol. 2021 Jul;10(7):2998-3009
pubmed: 34430403
Front Cell Dev Biol. 2019 Jan 24;7:2
pubmed: 30733945
Eur Urol Oncol. 2022 Feb;5(1):84-91
pubmed: 34920986
Eur Urol. 2018 Dec;74(6):784-795
pubmed: 30268659
Front Immunol. 2021 Oct 04;12:745332
pubmed: 34671359
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Cell. 2014 Mar 27;157(1):77-94
pubmed: 24679528
Cancer Lett. 2020 Aug 10;485:38-44
pubmed: 32437725
JAMA. 2020 Nov 17;324(19):1980-1991
pubmed: 33201207
Oncol Lett. 2021 May;21(5):373
pubmed: 33777197
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Nat Rev Urol. 2018 Oct;15(10):615-625
pubmed: 29991725